Fact CheckerSign in

NCT06643130RecruitingPhase 3

Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients With Hypertension and Dyslipidemia

A Multi-center, Randomized, Double-blind, Parallel, Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients With Hypertension and Dyslipidemia

Source: ClinicalTrials.gov · Last updated 9 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

A Multi-center, Randomized, Double-blind, Parallel, Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients with Hypertension and Dyslipidemia

Status (registry)
Recruiting
Phase (registry)
Phase 3
Study type
Interventional
Enrollment
162 (estimated)
First submitted
9 Oct 2024
Start date
2 Dec 2024
Primary completion date
30 Apr 2026
Lead sponsor
JW Pharmaceutical
NCT number
NCT06643130

What you commit to

  • Study type: Interventional · Phase 3
  • Planned participants: 162
  • From 2 Dec 2024 to the primary completion date, 30 Apr 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • The subject not meet the specified msBP and LDL-C level

Who the study is looking for

  • Patients with hypertension and dyslipidemia

Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Gangdong Sacred Heart Hospital
Coordinator of this site? Confirm its status		SeoulSouth KoreaRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.